Verrucous carcinoma of vulva
Verucous carcinoma of the vulva is a special low-grade squamous cell carcinoma, a special subtype of squamous cell carcinoma, with good histological differentiation and local invasive growth. Most of them are primary tumors that occur in macerated areas (such as the mouth, external genitalia, anus and plantar part), and can also occur on the basis of primary diseases such as chronic ulcers and suppurative hidradenitis drainage sinus. The tumor is well differentiated and low in malignancy. It slowly develops into a huge mass and can even block the vulva. Although the tumor looks terrible in the naked eye, it rarely metastasizes to regional lymph nodes.
-
Site of disease:
vulva -
Infectious :
Not contagious -
Frequent population:
Occurs in postmenopausal women in their 50s. -
Related symptoms:
Swollen inguinal lymph nodes ulcer secondary infection pain swollen inguinal lymph nodes -
Concurrent disease:
Related Drugs
Cisplatin
Indication: It is the first-line drug for the treatment of various solid tumors. Combination with VP-16 (EP regimen) is the first-line treatment for SCLC or NSCLC. Combination with MMC, IFO (IMP regimen), or NVB is the commonly used regimen for the treatment of NSCLC. Combination chemotherapy based on DDP is also the main treatment for advanced ovarian cancer, osteosarcoma and neuroblastoma. Combination with ADM, CTX, etc. is effective for squamous cell carcinoma and transitional cell carcinoma in multiple sites, such as head and neck, cervical, esophageal and urinary system tumors.
Manufacturer:
Qilu Pharmaceutical Co., Ltd.
Cisplatin for injection
Indication: It is a first-line drug for the treatment of various solid tumors. Combination with VP-16 (EP regimen) is a first-line regimen for the treatment of SCLC or NSCLC. Combination with MMC, IFO (IMP regimen), or NVB is a common regimen for the treatment of NSCLC. Combination chemotherapy based on DDP is also the main treatment for advanced ovarian cancer, osteosarcoma and neuroblastoma. Combination with ADM, CTX, etc. is effective for squamous cell carcinoma and transitional cell carcinoma in multiple sites, such as head and neck, cervix, esophagus and urinary system tumors. "PVB" (DDP, VLB, BLM) can treat most stage IV non-spermatogonia testicular cancers with a remission rate of 50% to 80%. In addition, this product is a radiotherapy sensitizer. It is currently widely used in foreign countries for local radiotherapy of stage IV inoperable NSCLC, which can improve efficacy and survival.
Manufacturer:
Shandong Fenghuang Pharmaceutical Co., Ltd.
Cinobufacini Injection
Manufacturer:
Anhui Huarun Jinchan Pharmaceutical Co., Ltd.
Related Ingredients